Showing 681 - 700 results of 1,388 for search '"immunosuppression"', query time: 0.05s Refine Results
  1. 681

    Hypophyseal Involvement in Immunoglobulin G4-Related Disease: A Retrospective Study from a Single Tertiary Center by Yang Liu, Linjie Wang, Wen Zhang, Hui Pan, Hongbo Yang, Kan Deng, Lin Lu, Yong Yao, Shi Chen, Xiaofeng Chai, Feng Feng, Hui You, Zimeng Jin, Huijuan Zhu

    Published 2018-01-01
    “…With GC and/or immunosuppressant treatment, however, pituitary function or diabetes insipidus did not improve considerably.…”
    Get full text
    Article
  2. 682

    Role of Myokines in Myositis Pathogenesis and Their Potential to be New Therapeutic Targets in Idiopathic Inflammatory Myopathies by Vlad Mageriu, Emilia Manole, Alexandra E. Bastian, Florica Staniceanu

    Published 2020-01-01
    “…Many patients, even after immunosuppressive therapy, do not respond to treatment, so new alternatives have been sought for this. …”
    Get full text
    Article
  3. 683

    Actinomyces Acute Rhinosinusitis Complicated by Subperiosteal Abscess in an Immunocompromised 12-Year-Old: Case Report and Literature Review by Sai V. Nimmagadda, Li-Xing Man, Margo K. McKenna, John J. Faria, Isaac L. Schmale

    Published 2022-01-01
    “…Our case is the first reported in a pediatric patient and the first taking immunosuppressive medication. Overall, only 3 cases of actinomyces rhinosinusitis in immunosuppressed individuals have been reported, each with uncontrolled diabetes and each also responded well to surgery and appropriate antibiotics. …”
    Get full text
    Article
  4. 684

    Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19 by Alhasan Alsalman, Mohammad A. Al-Mterin, Eyad Elkord

    Published 2022-01-01
    “…In conclusion, further studies are required to investigate the role and function of immunosuppressive cells and their potentials as prognostic biomarkers and therapeutic targets in COVID-19 patients.…”
    Get full text
    Article
  5. 685

    Polyoma BK Virus: An Oncogenic Virus? by Syed Hassan, Zaid Alirhayim, Syed Ahmed, Syed Amer

    Published 2013-01-01
    “…He subsequently developed BK virus nephropathy related to chronic immunosuppressant therapy. Three years later, misfortune struck again, and he developed adenocarcinoma of the bladder.…”
    Get full text
    Article
  6. 686

    Wernicke’s Encephalopathy: An Unusual Consequence of the Acquired Immune Deficiency Syndrome—Case Report and Literature Review by Timothy R. Larsen, Dritan Dragu, Michael Williams

    Published 2013-01-01
    “…Wernicke’s has been described in patients with acquired immune deficiency syndrome (AIDS); however, given these patients’ immunosuppressed state, the diagnosis of Wernicke’s encephalopathy is not apparent. …”
    Get full text
    Article
  7. 687

    A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy by Dong-Sup Chung, Hye-Jin Shin, Yong-Kil Hong

    Published 2014-01-01
    “…Moreover, enhanced biologic functions of T cells generated by genetic engineering and modified immunosuppressive microenvironment of host by homeostatic T cell expansion and/or elimination of immunosuppressive cells and molecules can induce more potent antitumor T cell responses and make this strategy hold promise in promoting a patient response for malignant glioma treatment. …”
    Get full text
    Article
  8. 688

    Acknowledging and addressing real-world challenges to treating immune-related adverse events by Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara

    Published 2024-07-01
    “…Currently, irAE treatment remains suboptimal in many areas, as many expert guidelines remain vague on the optimal selection, dosing, and duration of steroids and the use of other immunosuppressive agents. This coupled with delays in diagnosis and difficulties for patients accessing effective irAE treatment results in barriers to effective irAE care. …”
    Get full text
    Article
  9. 689

    It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma by Christin Knickmeier, Gaetan Aime Noubissi Nzeteu, Bernhard F. Gibbs, Frederik J. H. Hoogwater, Maarten W. Nijkamp, Maximilian Bockhorn, N. Helge Meyer

    Published 2025-01-01
    “…Gal-9 significantly contributes to the immunosuppressive milieu of PDAC by interacting with various immune cells, such as T cells, macrophages, and myeloid-derived suppressor cells (MDSCs). …”
    Get full text
    Article
  10. 690

    Immunomodulatory Effect of Bisphosphonate Risedronate Sodium on CD163+ Arginase 1+ M2 Macrophages: The Development of a Possible Supportive Therapy for Angiosarcoma by Taku Fujimura, Yumi Kambayashi, Sadanori Furudate, Aya Kakizaki, Setsuya Aiba

    Published 2013-01-01
    “…An imbalance of immunosuppressive cells and cytotoxic cells plays an important role in inhibiting the antitumor immune response of the tumor-bearing host. …”
    Get full text
    Article
  11. 691

    Application of Corticosteroids in Dentistry: A Review by Souptik Satpathi, Yogesh V. Rathod, Kamil N. Rajpari, Rohit Kandlikar, Y. Rajiv Kumar, Arti Gachake, Pratik Surana

    Published 2024-12-01
    “…Corticosteroids are crucial in dentistry for their anti-inflammatory and immunosuppressive properties, aiding in managing conditions such as oral lichen planus, recurrent aphthous stomatitis, and post-operative inflammation. …”
    Get full text
    Article
  12. 692

    Leclercia adecarboxylata Musculoskeletal Infection in an Immune Competent Pediatric Patient: An Emerging Pathogen? by W. Jeffrey Grantham, Shawn S. Funk, Jonathan G. Schoenecker

    Published 2015-01-01
    “…Leclercia adecarboxylata has increasing reports in immunosuppressed and adult patients with musculoskeletal infection. …”
    Get full text
    Article
  13. 693

    Invasive Group B Streptococcal Disease in Two Pediatric Patients with Systemic Lupus Erythematosus by Dongning Wu, Kenneth Bromberg, Roberto Jodorkovsky

    Published 2013-01-01
    “…We report two patients with SLE who were treated with steroids and immunosuppressive medication and then developed invasive Group B Streptococcus (GBS) infections. …”
    Get full text
    Article
  14. 694

    Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort... by Raj Tummala, Richard A Furie, Laurent Arnaud, Eric F Morand, Martin Aringer, Stephanie Chen, Barnabas Desta, Alberta Hoi, Bo Ding, Christine Peschken, Jonatan Hedberg, Tina Grünfeld Eén, Alessandro Sorrentino, Danuta Kielar

    Published 2025-01-01
    “…Disease activity (SLE Disease Activity Index 2000 (SLEDAI-2K)), average oral glucocorticoid dose and use of other treatments—specifically antimalarials, biologics and immunosuppressants—were measured over time. Subgroup analyses were stratified by baseline interferon gene signature (IFNGS) status and disease activity (SLEDAI-2K) status.Results Patient demographics and baseline characteristics were similar among subgroups; the majority of patients were on antimalarials (n=670; 81.1%), followed by glucocorticoids (n=537; 65.0%), immunosuppressants (n=453; 54.8%) and biologics (n=175; 21.2%). …”
    Get full text
    Article
  15. 695

    Unveiling immune cell response disparities in human primary cancer-associated fibroblasts between two- and three-dimensional cultures. by Jian-Ping Yang, Nikhil Nitin Kulkarni, Masashi Yamaji, Tsubasa Shiraishi, Thang Pham, Han Do, Nicole Aiello, Michael Shaw, Toshihiro Nakamura, Akiko Abiru, Narender R Gavva, Shane R Horman

    Published 2024-01-01
    “…Notably, 3D CAF-secreted proteins manifest a more immunosuppressive profile by enhancing monocyte transendothelial migration and differentiation into M2-like tumor-associated macrophages (TAMs). …”
    Get full text
    Article
  16. 696

    Anti-Factor H Antibodies in Egyptian Children with Hemolytic Uremic Syndrome by Shereen Shawky, Hesham Safouh, Mona Gamal, Mohammed M. Abbas, Azza Aboul-Enein, Toshihiro Sawai, Yosra Fahmy, Heba Selim

    Published 2021-01-01
    “…All patients who started immunosuppressives early together with plasmapheresis upon detection of their anti-FH had complete renal function recovery. …”
    Get full text
    Article
  17. 697

    Infections in systemic lupus erythematosus: A study of incidence and risk factors in 100 patients from western India by Ankan Jha, Tridip Das, Sunilkumar Rajmani Singh, Jyotsna Oak

    Published 2022-01-01
    “…Management of SLE needs vigilance for infection and judicious use of immunosuppressive drugs.…”
    Get full text
    Article
  18. 698

    Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease by Adrian Peacock, Frances C. Dehle, Oscar A. Mesa Zapata, Francesca Gennari, Maro R.I. Williams, Nada Hamad, Stephen Larsen, Simon J. Harrison, Colman Taylor

    Published 2024-02-01
    “…The analysis considered costs of second-line treatment and disease management including immunosuppressants, hospitalizations and subsequent therapy. …”
    Get full text
    Article
  19. 699

    Vascular Endograft Infection with Listeria monocytogenes reated with Surgical Debridement but without Graft Removal by Beate Tanner-Steinmann, Katia Boggian

    Published 2011-01-01
    “…The awareness of Listeria monocytogenes as a pathogen in meningitis and bacteremia in immunosuppressed patients is high. We report a case of vascular graft infection due to Listeria monocytogenes as an example of a less well-known manifestation of listeriosis and focus on the possible treatment procedures emphasizing a management with surgical debridement but preservation of the endograft, in contrast to the gold standard treatment of vascular graft infections which consists of a removal of the graft.…”
    Get full text
    Article
  20. 700

    Inflammatory demyelinating polyneuropathies and patient management during the COVID-19 pandemic. Literature review by R. Bunevičiūtė, A. Klimašauskienė

    Published 2020-06-01
    “…They can cause a lot of difficulties in daily practice due to their clinical heterogeneity and long term immunosuppressive treatment. Environmental and epidemiological changes may increase the incidence of the demyelinating polyneuropathies. …”
    Get full text
    Article